What if… Oral GLP-1 drugs replace injectable treatments

◇ Hypothetical scenario. What if… Oral GLP-1 drugs replace injectable treatments? The analysis positions GPCR, VKTX and LLY to benefit and NVO, ALT and STVN under pressure; confidence medium.

Hypothetical scenario — this analysis maps conditional exposure (“if this happens, who is exposed”). It is not graded against market prices unless the event occurs.

Analyzed 2026-09-23 — point-in-time, never revised. A hypothetical scenario is never graded.

Ranked exposures

  1. ▼ NVO Novo Nordisk — impact -81 · confidence medium · horizon weeks · 1st order
    Novo Nordisk loses premium injectable revenue as oral GLP-1 therapies replace Wegovy and Ozempic in treatment protocols.
    Chain: oral GLP-1 pills reach broad approval → prescribers default to tablets for new starts → Wegovy and Ozempic pen starts decline → payers push injectable net prices lower → Novo injectable franchise revenue growth slows
    What would break the call: Oral Wegovy capturing the majority of new oral starts keeps Novo total obesity revenue growing.
  2. ▲ GPCR Structure Therapeutics — impact +80 · confidence high · horizon quarters · 1st order
    Oral GLP-1 adoption expands Structure Therapeutics' revenue and valuation by replacing injectable obesity and diabetes treatments.
    Chain: oral GLP-1 class validated by pivotal data → small molecule developers gain partnering leverage → Structure lead asset aleniglipron valued higher → licensing or takeout economics improve
    What would break the call: Weak weight loss or tolerability data in Structure late stage trials breaks the read across.
  3. ▲ VKTX Viking Therapeutics — impact +78 · confidence high · horizon quarters · 1st order
    Oral GLP-1 adoption increases Viking Therapeutics' revenue by replacing injectable obesity treatments with needle-free chronic dosing.
    Chain: patients prefer needle free chronic dosing → oral obesity market expands rapidly → Viking oral VK2735 addressable market grows → partnering and pricing power improve
    What would break the call: Oral VK2735 tolerability or dose data disappoints in registrational trials.
  4. ▼ ALT Altimmune — impact -74 · confidence low · horizon weeks · 1st order
    Altimmune's injectable pemvidutide faces reduced adoption and weaker pricing as oral therapies remove needle burden.
    Chain: oral agents remove needle burden → injectable candidates face higher efficacy hurdle → pemvidutide commercial value discounted → financing and partnering terms worsen
    What would break the call: Pemvidutide MASH approval creates a liver indication where oral GLP-1 agents do not compete.
  5. ▼ STVN Stevanato — impact -73 · confidence medium · horizon quarters · 2nd order
    Stevanato Group loses pen system and injectable packaging demand as drugmakers shift GLP-1 production toward tablets.
    Chain: drugmakers shift GLP-1 output to tablets → pen cartridge and syringe orders fall → Stevanato drug delivery segment volume declines → high margin pen platform revenue shrinks
    What would break the call: Injectable GLP-1 volumes keep growing on supply expansion even as oral scripts rise.
  6. ▼ WST West Pharmaceutical — impact -70 · confidence medium · horizon quarters · 2nd order
    West Pharmaceutical sells fewer injectable containment components as GLP-1 treatment shifts from pens to tablets.
    Chain: GLP-1 production mix moves toward pills → fewer stoppers plungers and seals required → West high value product volumes decline → injectable containment revenue growth slows
    What would break the call: Biologics and other injectable launches replace lost GLP-1 component volume at similar pricing.
  7. ▲ LLY Eli Lilly — impact +68 · confidence medium · horizon quarters · 1st order
    Lilly expands obesity treatment by converting injectable users to daily orforglipron pills.
    Chain: orforglipron approved as oral obesity therapy → manufacturing scales without sterile fill constraints → Lilly converts injectable and naive patients → incretin franchise revenue and volume expand
    What would break the call: Orforglipron label carries liver or tolerability warnings that limit first line use.
  8. ▲ PFE Pfizer — impact +60 · confidence medium · horizon quarters · 1st order
    Pfizer rebuilds obesity revenue when its oral GLP-1 therapy captures patients from injectable competitors.
    Chain: Pfizer acquires oral obesity assets → oral class becomes standard therapy → Pfizer candidate takes share from injectables → obesity revenue line rebuilt
    What would break the call: Pfizer oral candidate fails a pivotal readout or lands behind Lilly by years.
  9. ▼ BDX Becton Dickinson — impact -58 · confidence high · horizon quarters · 2nd order
    Becton Dickinson sells fewer pen needles and syringes as oral GLP-1 therapies replace chronic injections.
    Chain: chronic weekly injections replaced by tablets → pen needle and syringe demand falls → pharmacy reorder volumes decline → BDX medical segment consumable revenue slows
    What would break the call: Insulin and biologic injection volumes grow enough to offset lost GLP-1 pen needle units.
  10. ▼ AMGN Amgen — impact -57 · confidence medium · horizon quarters · 1st order
    Amgen's injectable obesity candidate loses commercial potential as effective oral GLP-1 therapies become standard treatment.
    Chain: oral agents set convenience benchmark → monthly injectable MariTide differentiation narrows → peak sales estimates cut → obesity program value discounted
    What would break the call: MariTide shows clearly superior weight loss and durability that oral agents cannot match.
  11. ▼ ATR AptarGroup — impact -54 · confidence low · horizon quarters · 2nd order
    AptarGroup loses drug delivery component volume when pharmaceutical customers reduce pen and injector output.
    Chain: pharma customers cut injector build plans → Aptar pharma dispensing and injectable components decline → segment volume and mix weaken → pharma segment margin compresses
    What would break the call: Nasal and other drug delivery growth offsets declining injectable component volumes.
  12. ▼ EMBC Embecta — impact -52 · confidence medium · horizon quarters · 2nd order
    Embecta sells fewer pen needles as oral GLP-1 regimens replace routine injections.
    Chain: GLP-1 patients move to tablets → pen needle attach rate falls → Embecta unit volumes decline → already flat revenue base deteriorates
    What would break the call: Insulin using diabetics remain on injections regardless of oral GLP-1 uptake.
  13. ▲ AZN AstraZeneca — impact +50 · confidence low · horizon quarters · 1st order
    AstraZeneca oral GLP-1 portfolio expands revenue after patients substitute away from injectable treatments.
    Chain: oral GLP-1 becomes preferred format → AstraZeneca advances oral candidate AZD5004 → late entrant still gains share → cardiometabolic revenue base expands
    What would break the call: AstraZeneca oral candidate discontinued or delayed beyond a competitive launch window.
  14. ▲ HIMS Hims & Hers Health — impact +44 · confidence low · horizon quarters · 2nd order
    Hims & Hers processes more recurring obesity prescriptions as oral medicines simplify telehealth prescribing and pharmacy fulfillment.
    Chain: oral obesity drugs simplify prescribing → telehealth onboarding and refills get easier → Hims subscriber additions accelerate → recurring weight loss revenue grows
    What would break the call: Branded oral makers restrict telehealth channel access or enforce direct to consumer exclusivity.
  15. ▲ TMO Thermo Fisher — impact +42 · confidence low · horizon quarters · 2nd order
    Thermo Fisher redirects capacity toward high volume oral solid dose manufacturing, capturing tablet production contracts from obesity drug sponsors.
    Chain: sponsors need massive oral solid dose capacity → tablet API and formulation contracts awarded → Thermo pharma services backlog grows → CDMO segment revenue and utilization rise
    What would break the call: Lilly and peers keep oral manufacturing in house and with non listed partners.
  16. ▼ PODD Insulet — impact -40 · confidence low · horizon quarters · 2nd order
    Insulet drug delivery device sales decline when oral GLP-1 drugs replace injectable treatments.
    Chain: oral therapy reduces injectable device need → drug delivery partnership opportunities shrink → Insulet adjacent growth optionality fades → sentiment on device exposed names weakens
    What would break the call: Type 1 and type 2 pump adoption keeps compounding independent of obesity drug format.
  17. ▲ MRK Merck — impact +40 · confidence low · horizon quarters · 1st order
    Merck oral GLP-1 candidates produce higher returns by taking the place of injectable drugs in prescriptions.
    Chain: oral obesity market validated → Merck advances licensed oral GLP-1 candidate → pill format fits primary care distribution → new revenue offsets Keytruda expiry
    What would break the call: Merck oral candidate posts mid single digit weight loss and is deprioritized.
  18. ▲ COR Cencora — impact +38 · confidence low · horizon quarters · 2nd order
    Cencora distributes oral tablets at lower handling cost, expanding unit volume through mail order and retail pharmacy channels.
    Chain: obesity scripts shift to tablets → ambient shipping replaces refrigerated pen handling → Cencora distributes higher unit volumes cheaply → specialty distribution revenue and margin improve
    What would break the call: Manufacturers move oral GLP-1 to direct to patient channels that bypass wholesalers.
  19. ▲ MCK McKesson — impact +36 · confidence low · horizon quarters · 2nd order
    McKesson gains distribution volume because pill formats broaden eligible patients and simplify shipping versus refrigerated pen injectors.
    Chain: oral formats broaden treated population → pharmacy script volumes expand → McKesson handles more units per patient → distribution revenue and operating profit grow
    What would break the call: Direct to consumer pharmacy programs from manufacturers bypass wholesale distribution.
  20. ▼ CDXS Codexis — impact -35 · confidence low · horizon quarters · 2nd order
    Codexis supplies enzymes for peptide synthesis, so small molecule pills reduce demand for its manufacturing biocatalysts.
    Chain: small molecule tablets replace peptide injectables → peptide API manufacturers cut synthesis volumes → enzyme and biocatalyst orders decline → Codexis pharma manufacturing revenue slows
    What would break the call: Oral semaglutide volumes expand peptide synthesis demand and lift Codexis enzyme orders instead.
  21. ▼ TNDM Tandem Diabetes — impact -35 · confidence low · horizon quarters
    Tandem Diabetes insulin pump volumes drop as patients choose oral GLP-1 drugs in place of injectables.
  22. ▲ CVS CVS Health — impact +34 · confidence medium · horizon quarters
    CVS increases pharmacy prescription volume as oral GLP-1 therapies shift obesity treatment from injections to retail channels.
  23. ▼ CYRX Cryoport — impact -25 · confidence low · horizon quarters
    Cryoport moves temperature controlled pharmaceutical freight, and shelf stable pills remove the refrigeration requirement driving those shipments.
  24. ▲ WMT Walmart — impact +22 · confidence low · horizon quarters
    Walmart pharmacies stock shelf stable obesity tablets cheaply, driving cash pay script traffic and repeat store visits.

More

Related scenarios

Stocks in this scenario

NVO · GPCR · VKTX · ALT · STVN · WST · LLY · PFE · BDX · AMGN · ATR · EMBC · AZN · HIMS · TMO · PODD · MRK · COR · MCK · CDXS · TNDM · CVS · CYRX · WMT · GLW · RGEN · TEVA · DHR · SHC

Community · All scenarios · Pricing · Track record · Methodology · Map your own scenario